( EVANSTON Ill.--(BUSINESS WIRE)--Apr 26...)Northfield Laboratories Investor Update,Health

EVANSTON, Ill.--(BUSINESS WIRE)--Apr 26, 2007 - Northfield Laboratories Inc. (Nasdaq: NFLD) announced today that its contract research organization has informed the Company that the report of the summary data from its pivotal Phase III trauma trial with PolyHeme(R), the Company's human-hemoglobin based oxygen-carrying red cell substitute, will not be complete until May.

About Northfield Laboratories

Northfield Laboratories Inc. is a leader in developing an oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss, when an oxygen-carrying fluid is required and red blood cells are not available. PolyHeme(R) is a solution of chemically modified human hemoglobin that requires no cross matching and is therefore compatible with all blood types. It has a shelf life in excess of 12 months. For further information, visit www.northfieldlabs.com.

Forward Looking Statement

This press release may contain forward-looking statements concerning, among other things, Northfield's future business plans and strategies and clinical and regulatory developments affecting our PolyHeme red blood cell substitute product. These forward-looking statements are identified by the use of such terms as "intends," "expects," "plans," "estimates," "anticipates," "should," "believes" and similar terms. These forward-looking statements involve inherent risks and uncertainties. Our actual results may therefore differ materially from those predicted by the forward-looking statements because of various factors and possible events, including the possibility that the final data from our Phase III clinical trial, once available, may not be sufficient to demonstrate the safety or effectiveness of PolyHeme, our ability to obtain FDA approval to market PolyHeme commercially, our ability to obtain Fast Track designation and priority review, the availability of capital to finance our clinical trials and ongoing business operations, our ability to obtain ade
'"/>

Page: 1 2
Related medicine technology :

1. Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study
2. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
3. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
4. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
5. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
6. Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007
7. Acorda Therapeutics to Host Analyst and Investor Reception
8. Isis Pharmaceuticals Announces Its Participation at the Upcoming ACC 56th Annual Scientific Session in New Orleans and Its Live Analyst/Investor Webcast Presentation
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Avexas Apricitabine Clinical Trial Update
11. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial